金陵药业:2024年报净利润0.4亿 同比下降62.26%

Financial Performance - The basic earnings per share decreased by 67.63% to 0.0682 yuan in 2024 from 0.2107 yuan in 2023 [1] - Net profit fell by 62.26% to 0.4 billion yuan in 2024 compared to 1.06 billion yuan in 2023 [1] - Operating revenue increased by 2.72% to 32.81 billion yuan in 2024 from 31.94 billion yuan in 2023 [1] - The return on equity dropped by 66.97% to 1.09% in 2024 from 3.30% in 2023 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 29,652.44 million shares, accounting for 50.22% of the circulating shares, with a change of 4.19 million shares from the previous period [1] - Nanjing New Industry Investment Group Co., Ltd. remains the largest shareholder with 22,794.38 million shares, representing 38.61% of total share capital [2] - New entrants among the top shareholders include Liu Ping and Nanjing Xiechen Electronic Technology Co., Ltd. [2] Dividend Distribution - The company announced a dividend distribution plan of 1 yuan per share (including tax) [3]